Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
George I. Papakostas
With
Pamlab, L.L.C.
The study consists of two phases, each lasting a total of four weeks (8 weeks total), with visits at the DCRP every 10 days. If the subject is eligible, they will be asked to return two weeks later for a baseline visit, when they will be randomly assigned, like a flip of a coin, to one of three treatment groups: a) drug/drug, b) placebo/drug, c) placebo/placebo (a placebo is a pill that looks like a study drug but contains no active medication). They will have a greater than 50% chance of receiving active medication (Deplin) at some point in the 8 week study.
Neither the subject nor the research staff will know which group the subject is in.
All subjects will be asked to take the study medication in the morning, in addition to their ongoing SSRI treatment.
Age
18–65
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
18-65 years old
Meet criteria for current Major Depressive Disorder
Currently taking an SSRI
You may not be if
Pregnant women
Unstable medical illness including cardiovascular, hepatic, renal, respiratory, endocrine, neurological, or hematological disease
Prior course of MTHF augmentation, or intolerance to MTHF at any dose
Substance use disorders active within the last six months, any bipolar disorder (current or past), any psychotic disorder (current or past)
Have failed more than 2 adequate antidepressant trials during the current Major Depressive Episode